New Objective网络研讨会：乙肝病毒的蛋白质组学鉴定|再生元制药

February 15, 2023 – Littleton, MA (USA) Mike Lee, CEO, together with Emily Ehrenfeld, Co-Founder and President, New Objective hosted an event featuring the heated PicoChip as a standardized platform for Immunopeptidomic research conducted at Regeneron. As Emily shared during the opening remarks: “The benefit of the patient is at the forefront of all we do.”

Amanda Berg, Vice President, New Objective, introduced the Heated PicoChip platform developed by New Objective - “An easy-to-use solution that transforms emitters to meaningful results.” The PicoChips deliver a high performance, robust, reproducible and reliable solution for clinical proteomic applications.

Helena Svobodova, Product Manager, New Objective welcomed and introduced Robert Salzler and about the beginning of his relationship with New Objective. “It started with a call from Mike to Robert, and working together on an industrialized platform. Today we are celebrating Robert’s work on immunopeptidomics.”

Robert Salzler, Team Leader for Immunopeptidomics (Discovery and Targeted) for Oncology, Infectious Disease and Autoimmunity, Regeneron shared the overview of various antibody therapies developed at Regeneron to address some of the most pressing health issues today by putting patient first at every stage of the clinical research.

Robert highlighted his experience with New Objective products and how the relationship with New Objective developed from a simple emitter request to working with state of the art solutions. The Heated PicoChip columns deliver the desired results  - “Very happy with these - will be the foundation of our system.” “The heated PicoChip lasts about a month with little to no interference.”

Robert then introduced his colleague Mayank Srivastava, Scientist, Proteomics and Immunopeptidomics at Regeneron and lead researcher on the recent publication on Proteogenomic identification of Hepatitis B virus (HBV) genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues. Mayank talked about the genomic variability of the HBV virus which when combined with the genomic difference in the patients make it very difficult to develop effective antibodies. “This virus integrates into the human genome randomly.”

The above artical can be found at: https://pubmed.ncbi.nlm.nih.gov/36582233/

To address these challenges, Regeneron developed a patient specific database of viral peptides which along with HLA genotypes are used for target selection. As Mayank stated: “Mass spec is a discovery engine!”

We invite you to join the ongoing communication and celebration of research featuring our customers and collaborators. To quote Robert: “We are sharing one project – but we have hundreds of projects.” We look forward to our ongoing discussion.